CNBC: Sanofi Pompe Disease Drug Supply Disruptions Continue, Some US Patients Facing Delays Until Late November
According to CNBC, Sanofi's supply disruption for its Pompe disease medication is ongoing, with some infusion treatments for U.S. patients canceled or delayed due to shipping bottlenecks. The company stated that the impact could extend through late November. Sanofi attributed the shortage to manufacturing compliance remediation at its plant in Ireland, emphasizing that product quality is uncompromised and supply has begun to recover in certain countries. The report did not provide a definitive date for a full recovery, and it should not be inferred that all regions are experiencing complete stockouts or that the drug has been recalled.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
Strategy fell 6.4% from its previous close, currently trading at $90.320
-
2
Taiwan Capitalization Weighted Stock Index fell 3.31% from the previous close, currently trading at 38,864.60.
-
3
Hang Seng Index fell 1.52% from its previous close, currently trading at 22,941.09
-
4
CRO (Cronos) Price Pulls Back to $0.04135, Hitting Nearly 365-Day Low
-
5
Amazon rose 3.82% from its previous close, currently trading at $267.740
-
6
The Shanghai Composite Index fell 1.05% from its previous close, currently trading at 3,550.32.
-
7
The Taiwan Capitalization Weighted Stock Index (TAIEX) fell 3.81% from its previous close, currently standing at 38,665.32.
-
8
CNBC: Net Foreign Inflows to India Exceed $10 Billion in November, Analysts Warn Over Persistence of Inflation Impact
-
9
Bloomberg: A-Cap's flagship life insurer seeks to defer policyholder payments while exploring sale
-
10
Anthropic is set to go public on Nasdaq on Thursday, with the offering price set at $83 per share and a valuation of at least $1.4 trillion.
Markets Today
Recommended Reading


